Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function

Abstract

Background-Reduced renal function is associated with a poorer prognosis and increased bleeding risk in patients with acute coronary syndromes and may therefore alter the risk-benefit ratio with antiplatelet therapies. In the Platelet

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary

“…194 Ticagrelor was superiorto clopidogrel in ACS with renal impairment. 195 There is no convincing evidence that clopidogrel or the newer drugs are any more or less effective with DM than without. 188 …”

How to manage prasugrel and ticagrelor in daily practice

“…In the subgroup of patients with chronic kidney disease included in the PLATO study [42] ticagrelor was found to be associated with a 4.7% absolute risk reduction of death from vascular causes, myocardial infarction or stroke, and a 4.0% absolute risk reduction in total mortality compared to clopidogrel. In patients with renal insufficiency, ticagrelor may thus provide a greater reduction of ischaemic events, contrary to what has been shown with thienopyridines in major trials such CURE, CREDO and TRITON-TIMI38 [43].…”

Cardiovascular Risk and Chronic Kidney Disease: Cardio-Nephroprotection Strategies

“…Есть данные, что у больных ХБП часто развиваются кровотечения вслед-ствие передозировки антитромботических препаратов, дозы которых, при преимущественно почечном пути выведения, нуждаются в коррекции с учетом функцио-нального состояния почек (табл. 18) [73][74][75].…”